Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
暂无分享,去创建一个
B Romanowski | H. Kitchener | M. Lehtinen | S. Garland | X. Castellsagué | F. Bosch | J. Hedrick | F. Aoki | S. Chow | D. Apter | J. Paavonen | P. Naud | J. Salmerón | S. Skinner | U. Jaisamrarn | G. Limson | F. Struyf | G. Dubin | T. Schwarz | A. Szarewski | B. Romanowski | W. Poppe | D. Descamps | J Paavonen | D. Jenkins | T. Zahaf | A Szarewski | H Kitchener | M Lehtinen | J Salmerón | FY Aoki | P Naud | CM Wheeler | S-N Chow | D Apter | X Castellsague | JC Teixeira | SR Skinner | J Hedrick | U Jaisamrarn | G Limson | S Garland | TF Schwarz | WAJ Poppe | FX Bosch | D Jenkins | K Hardt | T Zahaf | D Descamps | F Struyf | G Dubin | S. Garland | T. Schwarz | K. Hardt | F. Bosch | H. Kitchener | F. Aoki | C. Wheeler | J. Teixeira | W. Poppe | S. R. Skinner | Genara Limson
[1] David R. Scott,et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.
[2] S. Coughlin,et al. Burden of cervical cancer in the United States, 1998–2003 , 2008, Cancer.
[3] M. Lehtinen,et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[4] F. Bray,et al. Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries , 2005, Cancer Epidemiology Biomarkers & Prevention.
[5] Qi Jiang,et al. Independent Data Monitoring Committees , 2010 .
[6] W. Quint,et al. Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.
[7] C. Key,et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. , 2000, Gynecologic oncology.
[8] Thomas Breuer,et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. , 2008, Vaccine.
[9] C. Poole,et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.
[10] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[11] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[12] B. Monk,et al. Age Considerations When Vaccinating against Hpv , 2008 .
[13] W. Quint,et al. Persistence of an Incident Human Papillomavirus Infection and Timing of Cervical Lesions in Previously Unexposed Young Women , 2009, Cancer Epidemiology Biomarkers & Prevention.
[14] Elizabeth R Unger,et al. Prevalence of HPV infection among females in the United States. , 2007, JAMA.
[15] L. Pinto,et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine , 2008, Human vaccines.
[16] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[17] J. Dungan. Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial , 2008 .
[18] F. X. Bosch,et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.
[19] E. Dasbach,et al. The health and economic burden of genital warts in a set of private health plans in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] P. Rosenberg,et al. Etiologic Heterogeneity for Cervical Carcinoma by Histopathologic Type, Using Comparative Age-Period-Cohort Models , 2009, Cancer Epidemiology Biomarkers & Prevention.
[21] C. Wheeler,et al. Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.
[22] M Arbyn,et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis , 2006, The Lancet.
[23] A. Giuliano,et al. Prevalence of HPV infection among men: A systematic review of the literature. , 2006, The Journal of infectious diseases.
[24] B. Spiessens,et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials , 2009, Human vaccines.
[25] M. Lehtinen,et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing , 2006, International journal of STD & AIDS.
[26] R. Herrero. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. , 2009, The Journal of infectious diseases.
[27] C. Wheeler,et al. Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial , 2007 .
[28] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.
[29] S. Wacholder,et al. CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3: Results from a Histological Review of Population-Based Cervical Samples , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[30] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.
[31] W. Prendiville,et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.
[32] Brigitte Colau,et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.
[33] D. Jenkins. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. , 2008, Gynecologic oncology.
[34] N. Kiviat,et al. Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.